The deal, which brings Nestle’s total investment to $273 million, raises Nestle’s stake in the drug developer to about 19 percent from 14.5 percent. The two companies also extended their two-year pact to develop therapies for food allergies by two years.
In the U.S. there is no approved treatment for peanut allergies, so drugmakers see a huge opportunity in the market.
Read the full report here.
More articles on pharmacy:
Walgreens managers lose thousands in bonuses: 3 things to know
14 pharma companies post Q3 profits over $1B
Neulasta biosimilar will get $4,175 price tag
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
